501 Shares in Eli Lilly and Company $LLY Bought by Shah Wealth Advisors LLC

Shah Wealth Advisors LLC acquired a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 501 shares of the company’s stock, valued at approximately $580,000.

Other large investors also recently made changes to their positions in the company. Bank of America Corp DE acquired a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $13,522,666,000. Jupiter Topco LLC acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $4,667,180,000. Corient Private Wealth LP acquired a new stake in Eli Lilly and Company in the 2nd quarter valued at $764,116,000. BlackRock Inc. increased its holdings in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. Finally, State Street Corp raised its position in Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Jefferies Financial Group boosted their price objective on Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the stock a “buy” rating in a research note on Monday, November 9th. Bank of America reiterated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a report on Tuesday, October 20th. UBS Group boosted their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, TD Cowen reissued a “buy” rating and set a $1,250.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,416.64.

Check Out Our Latest Stock Report on LLY

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,444.05 on Monday. The business’s 50 day moving average is $1,242.25 and its two-hundred day moving average is $1,110.30. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,460.00. The firm has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a PEG ratio of 1.73 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter last year, the company earned $7.02 earnings per share. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. Analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.